製品番号: HY-N2112

Glaucocalyxin A

2 Cited Publications

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Glaucocalyxin A, an ent-kauranoid diterpene from Rabdosia japonica var., induces apoptosis in osteosarcoma by inhibiting nuclear translocation of Five-zinc finger Glis 1 (GLI1) via regulating PI3K/Akt signaling pathway. Glaucocalyxin A has antitumor effect.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.88%
CAS 番号: 79498-31-0
分子式: C₂₀H₂₈O₄
分子量:332.43

保管条件:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Glaucocalyxin A 構造式

CAS 番号: 79498-31-0

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
化学情報
Publications (2)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

PI3K

PI3K アイソフォーム固有の製品をすべて表示 :

Akt アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	5.39 μM Compound: 18	Cytotoxicity against human A549 cells after 48 hrs by SRB method Cytotoxicity against human A549 cells after 48 hrs by SRB method	[PMID: 19425589]
A549	IC₅₀	7.5 μM Compound: GLA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25164762]
B16	IC₅₀	4.84 μM Compound: GLA	Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay	[PMID: 25164762]
HL-60	IC₅₀	5.52 μM Compound: GLA	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 25164762]
KB	IC₅₀	6.47 μM Compound: GLA	Antiproliferative activity against human KB cells after 48 hrs by MTT assay Antiproliferative activity against human KB cells after 48 hrs by MTT assay	[PMID: 25164762]
L02	IC₅₀	8.62 μM Compound: GLA	Antiproliferative activity against human HL7702 cells after 48 hrs by MTT assay Antiproliferative activity against human HL7702 cells after 48 hrs by MTT assay	[PMID: 25164762]
MCF7	IC₅₀	8.73 μM Compound: 18	Cytotoxicity against human MCF7 cells after 48 hrs by SRB method Cytotoxicity against human MCF7 cells after 48 hrs by SRB method	[PMID: 19425589]
NB-4	IC₅₀	2.9 μM Compound: 18	Cytotoxicity against human NB4 cells after 48 hrs by SRB method Cytotoxicity against human NB4 cells after 48 hrs by SRB method	[PMID: 19425589]
PC-3	IC₅₀	>10 μM Compound: 18	Cytotoxicity against human PC3 cells after 48 hrs by SRB method Cytotoxicity against human PC3 cells after 48 hrs by SRB method	[PMID: 19425589]
Platelet	IC₅₀	13.7 μM Compound: GLA	Inhibition of PAF-induced platelet aggregation in rabbit platelet suspension preincubated for 10 mins followed by PAF stimulation by turbidimetric method Inhibition of PAF-induced platelet aggregation in rabbit platelet suspension preincubated for 10 mins followed by PAF stimulation by turbidimetric method	[PMID: 32463237]
Platelet	IC₅₀	14.1 μM Compound: GLA	Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet suspension preincubated for 10 mins followed by AA stimulation by turbidimetric method Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet suspension preincubated for 10 mins followed by AA stimulation by turbidimetric method	[PMID: 32463237]
Platelet	IC₅₀	4.4 μM Compound: GLA	Inhibition of ADP-induced platelet aggregation in rabbit platelet suspension preincubated for 10 mins followed by ADP stimulation by turbidimetric method Inhibition of ADP-induced platelet aggregation in rabbit platelet suspension preincubated for 10 mins followed by ADP stimulation by turbidimetric method	[PMID: 32463237]
SGC-7901	IC₅₀	11.7 μM Compound: GLA	Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay	[PMID: 25164762]
SH-SY5Y	IC₅₀	>10 μM Compound: 18	Cytotoxicity against human SH-SY5Y cells after 48 hrs by SRB method Cytotoxicity against human SH-SY5Y cells after 48 hrs by SRB method	[PMID: 19425589]
SMMC-7721	IC₅₀	8.11 μM Compound: GLA	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 25164762]

体外実験

Glaucocalyxin A induces apoptosis by mitochondrial apoptotic pathway through several steps including increasing the Bax/Bcl-2 ratio, triggering the intracellular reactive oxygen species (ROS) generation, reducing mitochondrial membrane potential (MMP), and inducing cleavage of caspase-9 and caspase-3^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 79498-31-0
性状 Solid
分子量 332.43
分子式 C₂₀H₂₈O₄
Color White to off-white
SMILES

CC1(C)C(CC[C@@]2(C)[C@@]3([H])[C@@]4(C(C([C@H](CC3)[C@H]4O)=C)=O)[C@H](O)C[C@]12[H])=O
Structure Classification
- Terpenoids
- Diterpenoids
Initial Source
- Plants
- Labiatae
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Phytomedicine

Glaucocalyxin a protect liver function via inhibiting platelet over-activation during sepsis. [Abstract]

2022 Jun;100:154089. PMID: 35398736
Int J Mol Sci

Glaucocalyxin A Ameliorates Hypoxia/Reoxygenation-Induced Injury in Human Renal Proximal Tubular Epithelial Cell Line HK-2 Cells. [Abstract]

2021 Dec 31;23(1):446. PMID: 35008870

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (150.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0082 mL

15.0408 mL

30.0815 mL

5 mM

0.6016 mL

3.0082 mL

6.0163 mL

10 mM

0.3008 mL

1.5041 mL

3.0082 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (279 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Zhu J, et al. Glaucocalyxin A exerts anticancer effect on osteosarcoma by inhibiting GLI1 nucleartranslocation via regulating PI3K/Akt pathway. Cell Death Dis. 2018 Jun 13;9(6):708. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0082 mL	15.0408 mL	30.0815 mL	75.2038 mL
	5 mM	0.6016 mL	3.0082 mL	6.0163 mL	15.0408 mL
	10 mM	0.3008 mL	1.5041 mL	3.0082 mL	7.5204 mL
	15 mM	0.2005 mL	1.0027 mL	2.0054 mL	5.0136 mL
	20 mM	0.1504 mL	0.7520 mL	1.5041 mL	3.7602 mL
	25 mM	0.1203 mL	0.6016 mL	1.2033 mL	3.0082 mL
	30 mM	0.1003 mL	0.5014 mL	1.0027 mL	2.5068 mL
	40 mM	0.0752 mL	0.3760 mL	0.7520 mL	1.8801 mL
	50 mM	0.0602 mL	0.3008 mL	0.6016 mL	1.5041 mL
	60 mM	0.0501 mL	0.2507 mL	0.5014 mL	1.2534 mL
	80 mM	0.0376 mL	0.1880 mL	0.3760 mL	0.9400 mL
	100 mM	0.0301 mL	0.1504 mL	0.3008 mL	0.7520 mL

Keywords

Glaucocalyxin A

2 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Glaucocalyxin A

Apoptosis Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Cysteine Targeted Covalent Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Glaucocalyxin A

PI3K アイソフォーム固有の製品をすべて表示

Akt アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (2)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Glaucocalyxin A 関連分類

HY-N2112 関連分類